key: cord-0731011-6s9xcp29 authors: Liu, Ching-Hsuan; Lu, Cheng-Hua; Lin, Liang-Tzung title: Pandemic Strategies with Computational and Structural Biology against COVID-19: A Retrospective date: 2021-12-05 journal: Comput Struct Biotechnol J DOI: 10.1016/j.csbj.2021.11.040 sha: de46848af151259b86380d49075216f433b3b86c doc_id: 731011 cord_uid: 6s9xcp29 The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is the etiologic agent of the coronavirus disease 2019 (COVID-19) pandemic, has dominated all aspects of life for the better part of 2020 and into 2021. Research studies on the virus and exploration of therapeutic and preventive strategies has been moving at rapid rates to control the pandemic. In the field of computational and structural biology, recent research strategies have used multiple disciplines to compile large datasets to uncover statistical correlations and significance, visualize and model proteins, perform molecular dynamics simulations, and employ the help of artificial intelligence and machine learning to harness computational processing power to further the research on COVID-19, including drug screening, drug design, vaccine development, prognosis prediction, and outbreak prediction. These recent developments should help us better understand the viral disease and develop the much-needed therapies and strategies for the management of COVID-19. The coronavirus disease 2019 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is thought to have a zoonotic origin and started as an 39 outbreak in Wuhan, China, that later turned into a global pandemic. As of July 2021, the virus has led 40 to more than 184 million people infected and over 3.9 million deaths globally, despite periodic controls 41 (Center for Systems Science and Engineering at Johns Hopkins University, 2020). This number is way Artificial intelligence predicts the immunogenic 410 landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs Deep learning model for forecasting COVID-412 19 outbreak in Egypt AI Aided Design of Epitope-Based 415 Vaccine for the Induction of Cellular Immune Responses Against SARS-CoV-2 Early Stage Machine Learning-Based Prediction of US 417 County Vulnerability to the COVID-19 Pandemic: Machine Learning Approach Promising terpenes 420 as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: 421 Integrated computational approach Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection? Front 423 Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19 Post-acute COVID-19 syndrome Insights into SARS-CoV-2 genome, structure, evolution, 436 pathogenesis and therapies: Structural genomics approach Computational Structural Biology: Successes, Future 439 Directions, and Challenges. Molecules Vaxign-ML: supervised 441 machine learning reverse vaccinology model for improved prediction of bacterial protective antigens COVID-19 Coronavirus Vaccine Design Using Reverse 444 Vaccinology and Machine Learning Consensus document on the epidemiology of severe acute respiratory syndrome 446 (SARS). Geneva: World Health Organization Structure-based drug designing and immunoinformatics approach for SARS-CoV-2 A python based support vector regression model for prediction of 451 COVID19 cases in India Utilizing drug repurposing against COVID-19 -Efficacy, limitations, and 453 challenges Cross-neutralization of SARS-CoV-2 by a human monoclonal 458 SARS-CoV antibody De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike 461 Protein Forecasting spread of COVID-19 463 using google trends: A hybrid GWO-deep learning approach Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: 465 Introducing SpikePro. Viruses In silico studies 468 evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 469 pathogenesis Epitope-based chimeric 472 peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic 473 COVID-19: an in silico approach Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: 476 An Immunoinformatics Approach. Vaccines (Basel) Mortality Prediction Utilizing Blood Biomarkers to Predict the Severity of COVID-19 Using Machine 480 Learning Technique Short-term forecasting COVID-19 482 cumulative confirmed cases: Perspectives for Brazil Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Discovery of SARS-CoV-2 antiviral drugs through large-scale 493 compound repurposing Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) 496 inhibition Time Series Analysis and Forecast of the COVID-19 498 Pandemic in India using Genetic Programming Machine Learning Assisted Prediction of Prognostic Biomarkers 500 Associated With COVID-19, Using Clinical and Proteomics Data A human neutralizing antibody targets the receptor-binding 504 site of SARS-CoV-2 Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19 Prediction of the COVID-511 19 Pandemic for the Top 15 Affected Countries: Advanced Autoregressive Integrated Moving Average Mechanism of baricitinib supports artificial 517 intelligence-predicted testing in COVID-19 patients Coronavirus biology and replication: 519 implications for SARS-CoV-2 Glycyrrhizin Effectively Inhibits SARS-CoV-2 522 Replication by Inhibiting the Viral Main Protease. Viruses 524 Variants in SARS-CoV-2 associated with mild or severe outcome A human monoclonal antibody blocking SARS-527 CoV-2 infection Deep learning-530 based triage and analysis of lesion burden for COVID-19: a retrospective study with external validation COVID-19 drug repurposing: A review of computational screening methods, clinical 533 trials, and protein interaction assays COVID-19): A Review A new coronavirus associated with human respiratory disease in China A prediction model of outcome of 541 SARS-CoV-2 pneumonia based on laboratory findings Flavonoid Inhibitors Against COVID-19 3CL Proteinase Based on Virtual Screening Strategy Severity Detection for the Coronavirus Disease 2019 (COVID-19) Patients Using a 547 Machine Learning Model Based on the Blood and Urine Tests Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-550 ketoamide inhibitors CoV-2 by an antibody from a convalescent patient Conceptualization, Investigation, Writing -Original Draft Funding acquisition risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill, 361 26. 362 GUAN, X., ZHANG, B., FU, M., LI, M., YUAN, X., ZHU, Y., PENG, J., GUO